Ella Herzog
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ella Herzog has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Rony Dahan
Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel
56 shared publications - Alejandro Schaffer
Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
55 shared publications - Ansuman T. Satpathy
Department of Pathology, School of Medicine, Stanford University, Palo Alto, USA
55 shared publications - Chen Weller
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
55 shared publications - Colin J. Raposo
Department of Pathology, Stanford University
55 shared publications - Dean Ranmar
Weizmann Institute of Science 5 Department of Life Sciences Core Facilities Rehovot, Israel
55 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Elsevier in SSRN Electronic Journal
Enhanced Tumor Regulatory T Cells Selectivity through Affinity-Tuned Fc-Enhanced Bispecific Antibody
Regulatory T cells (Tregs) are central mediators of immunosuppression in tumors, therefore attractive targets for cancer immunotherapy. Fc-enhanced Treg-depleting antibodies emerge as a promising approach, yet clinical translation has been challenging due to compromised efficacy and treatment-associated side effects. Here, we demonstrate that Treg depletion using Fc-engineered antibodies targeting the clinically tested targets CD25 and CCR8 resulted in the nonspecific elimination of systemic Tregs and other lymphocyte populations within the tumor microenvironment, leading to compromised efficacy. Using high-dimensional transcriptomic and proteomic profiling, we identified marker pairs that specifically define highly activated tumor-associated Tregs (tuTregs). Bispecific antibodies (bsAbs) targeting these combinations showed preferential tuTreg selectivity. The lead candidate was an Fc-optimized affinity-attenuated CD25x4-1BB bsAb. It resulted in a superior anti-tumor activity than anti-CD25 and anti-4-1BB monotherapies, while exhibiting a reduced peripheral immune perturbation. These findings suggest that combining marker co-expression with controlled affinity and Fc-optimization provides a strategy to improve the therapeutic window of Treg-targeting antibodies.
- 4 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEnhanced Tumor Regulatory T Cells Selectivity through Affinity-Tuned Fc-Enhanced Bispecific Antibody
Regulatory T cells (Tregs) are central mediators of immunosuppression in tumors, therefore attractive targets for cancer immunotherapy. Fc-enhanced Treg-depleting antibodies emerge as a promising approach, yet clinical translation has been challenging due to compromised efficacy and treatment-associated side effects. Here, we demonstrate that Treg depletion using Fc-engineered antibodies targeting the clinically tested targets CD25 and CCR8 resulted in the nonspecific elimination of systemic Tregs and other lymphocyte populations within the tumor microenvironment, leading to compromised efficacy. Using high-dimensional transcriptomic and proteomic profiling, we identified marker pairs that specifically define highly activated tumor-associated Tregs (tuTregs). Bispecific antibodies (bsAbs) targeting these combinations showed preferential tuTreg selectivity. The lead candidate was an Fc-optimized affinity-attenuated CD25x4-1BB bsAb. It resulted in a superior anti-tumor activity than anti-CD25 and anti-4-1BB monotherapies, while exhibiting a reduced peripheral immune perturbation. These findings suggest that combining marker co-expression with controlled affinity and Fc-optimization provides a strategy to improve the therapeutic window of Treg-targeting antibodies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
Clinical data and characterization of the single-cell clones.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
Clinical data and characterization of the single-cell clones.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
List of antibodies used for IHC staining of human samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
List of antibodies used for IHC staining of human samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
ScRNA-seq characterization of Mif KO tumor clones.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
ScRNA-seq characterization of Mif KO tumor clones.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables- legends from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
Legends for the supplementary tables 1-10.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables- legends from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
Legends for the supplementary tables 1-10.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
Pathway enrichment in samples at day 0 post-inoculation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
Pathway enrichment in samples at day 0 post-inoculation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
Rejection and non-rejection gene sets identified in the scRNA sequencing analysis can stratify patients with high/low ITH and hot/cold tumor annotations.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
Rejection and non-rejection gene sets identified in the scRNA sequencing analysis can stratify patients with high/low ITH and hot/cold tumor annotations.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
Pathway enrichment in samples at days 6, 10, 16, and 20 post-inoculation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
Pathway enrichment in samples at days 6, 10, 16, and 20 post-inoculation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
CellChat and CellPhoneDB analyses reveal increased MIF signaling from tumor cells to macrophages in non-rejected clones.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
CellChat and CellPhoneDB analyses reveal increased MIF signaling from tumor cells to macrophages in non-rejected clones.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
Opal and CODEX multiplexed tissue imaging data shows infiltration of proliferative CD8+ T-cells to the rejected SCCs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
Opal and CODEX multiplexed tissue imaging data shows infiltration of proliferative CD8+ T-cells to the rejected SCCs.